Autogenous vaccines were introduced as evidence of their effectiveness against certain infections increased. These vaccines are based on activating the individual's immune system to produce immunity to the infectious agent and are generally made by an individual or a small group. Autogenous vaccines are quite similar to conventional vaccines in their application, but they differ and may be preferred over conventional vaccines in certain areas for veterinary use in different countries. The autogenous vaccines are limited and are approved for use by or under the supervision of a veterinarian, as well as non-veterinarians who have been approved by the government. They're used to treat bacterial and viral illnesses in cattle, poultry, pigs, birds, ruminants, horses, fish, rabbits, and other animals.
The autogenous vaccine market is being driven by the increasing allocation of funding from various governments and international communities of public and private benefactors to control and eradication programs. The increasing focus of government organizations on animal immunization is expected to spur market growth over the forecast period. The market is accelerated by the increasing focus on innovations for the prevention and treatment of zoonotic diseases. These factors have positively anticipated propelling the growth of the veterinary autogenous vaccines market in the United States. The constant developments in technologies and untapped potential in developing markets offer promising growth opportunities.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the United States autogenous vaccine market. In addition, complete analysis of changes on the United States autogenous vaccine market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
Autogenous vaccine market comprises of different market segment like by strain and end user.
The United States autogenous vaccine market includes key segments like bacterial strain and viral strain. The bacterial strain owning to the highest market share leads in the United States. Due to the increasing prevalence of bacterial infections among animal, increased funding and support for international animal disease eradication, preference toward bacterial strain vaccine autogenous vaccines over antibiotics are boosting the growth of bacterial strain in the United States.
The autogenous vaccine market finds its major end user in livestock farming companies, veterinary research institutes, veterinary clinics and hospitals. Veterinary clinics and hospitals segment dominates the market holding the largest market share and is expected to grow in the forecasted periods. Increase in the number of veterinary hospitals and rising government funding for animal healthcare is attributing the growth of veterinary clinics and hospitals segment in the region. Also the increased prevalence of bacterial infections and the growing awareness regarding eradication of animal disease are boosting the growth of veterinary clinics and hospitals in the United States.
The key players in autogenous vaccine market are Boehringer Ingelheim International, Elanco Animal Health, Ceva (Ceva Biovac), Phibro Animal Health Corporation, UVAXX Pte Ltd, Bimeda, Deltamune Animal Health, Epitopix, Genova Labs, Newport Laboratories, Hygieia Biological Laboratories, Vaxxinova, Elanco Animal Health, Addison Biological Laboratory, Phibro Animal Health Corporation and LOHMANN TIERZUCHT GmbH among others.
October 2019: Ceva entered into a license agreement with ProBioGen AG for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR technology.
September 2019: Agri Labs (Huvepharma, Inc.) established a new fermentation plant in Peshtera, Southern Bulgaria. This increases Huvepharma’s total production capacity by 30%. Huvepharma now has flexibility to ferment its entire current product portfolio in one place, with additional capacity remaining to introduce new products to their range in the future.
April 2018: Pharmaq announced the production of fish vaccines at a development center in Suzhou, China. Pharmaq, now owned by Zoetis, and the parent company is also ramping up vaccine R&D for other species.
March 2018: Apiam acquired Passionate Vetcare, a regional veterinary clinic in the north west of Bendigo, to support the opening of Apiam’s Bendigo Emergency & Referral Centre for servicing in the Central Victorian region.
March 2018: Ceva launched innovative programs to promote the production of autogenous poultry vaccines by focusing on more sustainable production.
The report analyses the autogenous vaccine market based on segment like by strain, end user. The bacterial strain leads the market due to increasing prevalence of bacterial infections among animals owing to the increasing prevalence of bacterial infections among animal and support for international animal disease eradication, preference toward bacterial strain. The autogenous vaccine market finds its major end user in livestock farming companies, veterinary research institutes, veterinary clinics and hospitals. Veterinary clinics and hospitals segment dominates the market holding the largest market share due to increase in the number of veterinary hospitals and rising government funding for animal healthcare is attributing the growth of veterinary clinics. The increasing prevalence of bacterial infections among animal, increased funding and support for international animal disease eradication, preference toward bacterial strain autogenous vaccines over antibiotics are boosting the growth of in the autogenous vaccine market in the United States.
Why to buy this report: